CVS Caremark is covering Zepbound again. Here is the fine print.
The largest formulary reversal of the GLP-1 era has a date: October 1, 2026. It also has a catch that most of the coverage headlines skipped.
On May 28, 2026, CVS Health announced that Caremark will add Zepbound (tirzepatide) back to its standard commercial formularies as an additional preferred option on October 1, 2026, alongside Wegovy, with commercial copays as low as $25 for eligible patients. The catch: plan sponsors — your employer or union — still decide whether GLP-1s for weight loss are covered at all. Preferred status is not the same thing as coverage.
- The full timeline, from exclusion to reversal: In May 2025, CVS Caremark announced it would drop Zepbound from its standard commercial formularies effective July 1, 2025, after negotiating a low....
- What “additional preferred option” actually means: Preferred status controls two things: whether the pharmacy claim processes without a formulary exception, and which cost tier the drug lands on.
- The $25 copay, and who actually gets it: Lilly and CVS describe commercial copays “as low as $25 per month” for eligible patients through copay-assistance arrangements.
- Your options between now and October 1: If your Caremark plan currently excludes Zepbound, you have four routes for the next few months.
- The employer opt-out is the number that matters: Roughly half of large employers cover GLP-1s for weight loss, and the cost pressure that pushed CVS to drop Zepbound in 2025 has not gone away — GL....
The full timeline, from exclusion to reversal
In May 2025, CVS Caremark announced it would drop Zepbound from its standard commercial formularies effective July 1, 2025, after negotiating a lower net cost for Novo Nordisk's Wegovy. Caremark became the only one of the three major pharmacy benefit managers to exclude Zepbound; Express Scripts and Optum Rx kept covering it.
The backlash was immediate and measurable. A Truveta analysis of more than 700,000 patients found that monthly switching away from tirzepatide jumped from roughly 0.6 percent before the change to 10.2 percent in June and July 2025. In September 2025, patients filed a class-action lawsuit arguing that Wegovy and Zepbound are not medically interchangeable — a position supported by the SURMOUNT-5 head-to-head trial, in which tirzepatide produced greater average weight loss than semaglutide.
On May 28, 2026, CVS reversed course: Zepbound returns October 1, 2026 as an additional preferred option, and the new-to-market block on Foundayo (orforglipron), Lilly's oral GLP-1 approved in April 2026, was removed effective June 1, 2026.
| Route | Available | Typical cost | Key requirement |
|---|---|---|---|
| Caremark preferred coverage | Oct 1, 2026 | $25–$60/mo copay | Plan covers weight-loss GLP-1s + PA |
| Formulary exception (now) | Today | Plan copay if approved | Documented Wegovy failure/intolerance |
| OSA indication PA | Today | Plan copay if approved | Sleep-study-confirmed moderate–severe OSA |
| Medicare GLP-1 Bridge | Jul 1, 2026 | ~$50/mo | Eligible Part D beneficiaries |
| LillyDirect self-pay vials | Today | $349–$499/mo | Cash pay; no insurance billing |
| Compounded tirzepatide | Today | $147–$259/mo verified | Not FDA-approved; telehealth eligibility |
What “additional preferred option” actually means
Preferred status controls two things: whether the pharmacy claim processes without a formulary exception, and which cost tier the drug lands on. From October 1, both Wegovy (injection and pill) and Zepbound sit as co-preferred options on Caremark's template commercial formularies — a list that covers roughly 25 to 30 million Americans.
It does not control the third and decisive thing: whether your specific plan covers weight-loss GLP-1s at all. Plan sponsors that adopt Caremark's template formularies retain discretion to customize or exclude the category entirely. If your employer has excluded weight-management drugs, October 1 changes nothing for you, and no appeal can force a benefit that the plan design excludes.
The $25 copay, and who actually gets it
Lilly and CVS describe commercial copays “as low as $25 per month” for eligible patients through copay-assistance arrangements. That figure assumes three things line up: your plan covers weight-loss GLP-1s, you meet the plan's prior-authorization criteria (typically BMI thresholds plus documentation), and you are commercially insured — manufacturer copay cards cannot be used with Medicare or Medicaid.
Medicare Part D members have a separate new path: the Medicare GLP-1 Bridge demonstration, a CMS pilot running from July 1, 2026, that gives eligible Part D beneficiaries access to certain GLP-1s for around $50 per month. That program is independent of the Caremark formulary change and has its own eligibility rules.
Your options between now and October 1
If your Caremark plan currently excludes Zepbound, you have four routes for the next few months. First, a formulary exception: most plans required documented failure or intolerance of Wegovy before approving Zepbound, and denial letters spell out the exact trial length the plan wants to see. Second, the obstructive sleep apnea pathway: Zepbound is separately FDA-approved for moderate-to-severe OSA in adults with obesity, and a sleep-study-confirmed diagnosis can open a different prior-authorization door.
Third, cash pay through LillyDirect, which sells Zepbound single-dose vials at self-pay prices well below retail. Fourth, compounded tirzepatide through telehealth programs — the lowest-cost route in our verified pricing, but one that involves non-FDA-approved compounded medication and its own legal and quality trade-offs, covered in our compounded GLP-1 safety review.
The employer opt-out is the number that matters
Roughly half of large employers cover GLP-1s for weight loss, and the cost pressure that pushed CVS to drop Zepbound in 2025 has not gone away — GLP-1s remain one of the largest line items in commercial drug spend. Caremark's announcement explicitly frames the return as available “for plan sponsors who elect to provide coverage.”
Practically: call the number on your insurance card or ask HR one precise question — “Did our plan adopt the October 1, 2026 GLP-1 formulary update, and are weight-loss medications covered or excluded?” The answer determines whether anything in this article applies to you.
Why CVS reversed, and what it signals
CVS says negotiations with both manufacturers produced an additional 10 to 15 percent in class-wide savings, making a two-drug preferred tier affordable. The competitive backdrop did the rest: brand list prices have been falling, LillyDirect and NovoCare created direct cash channels that bypass PBMs entirely, and the class-action suit made single-drug exclusion a legal liability as well as a member-relations problem.
For patients, the structural lesson is that formulary exclusions of non-interchangeable drugs are increasingly hard to defend. Tirzepatide and semaglutide produce different average outcomes in head-to-head data; a formulary that forces a switch between them is making a clinical decision, and 2025–2026 showed that patients, courts, and ultimately the PBM itself would not sustain it.
Frequently asked questions
Does the October 1 change guarantee my Zepbound is covered?
No. It restores Zepbound to Caremark's template preferred list, but your employer or plan sponsor decides whether weight-loss GLP-1s are covered at all. Confirm with your specific plan.
I was forced from Zepbound to Wegovy in 2025. Can I switch back?
From October 1, plans that adopt the update will treat both as preferred, so switching back becomes a clinical decision between you and your prescriber rather than a formulary fight. Ask your prescriber about re-titration rather than resuming your old dose.
Is Mounjaro affected?
No. The 2025 exclusion and the 2026 restoration concern Zepbound, the obesity indication of tirzepatide. Mounjaro, the type 2 diabetes indication, remained covered under diabetes criteria throughout.